Enrico Lupia Selected Research

Thrombopoietin (c-mpl Ligand)

6/2021	Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus.
2/2021	Cooperative Role of Thrombopoietin and Vascular Endothelial Growth Factor-A in the Progression of Liver Cirrhosis to Hepatocellular Carcinoma.
1/2017	Thrombopoietin as Early Biomarker of Disease Severity in Patients With Acute Pancreatitis.
1/2016	Blockade of Thrombopoietin Reduces Organ Damage in Experimental Endotoxemia and Polymicrobial Sepsis.
10/2014	May thrombopoietin be a useful marker of sepsis severity assessment in patients with SIRS entering the emergency department?
6/2013	Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department.
9/2010	Thrombopoietin modulates cardiac contractility in vitro and contributes to myocardial depressing activity of septic shock serum.
12/2006	Thrombopoietin contributes to enhanced platelet activation in patients with unstable angina.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Enrico Lupia Research Topics

Disease

12	Sepsis (Septicemia) 02/2022 - 06/2013
4	Septic Shock (Toxic Shock Syndrome) 06/2021 - 09/2010
4	Acute Aortic Syndrome 01/2021 - 02/2016
4	Aortic Dissection 10/2020 - 02/2013
3	Infections 02/2022 - 10/2014
3	Systemic Inflammatory Response Syndrome (Sepsis Syndrome) 01/2018 - 07/2013
3	Nephrotic Syndrome (Syndrome, Nephrotic) 01/2017 - 04/2003
3	Pancreatitis 01/2017 - 12/2004
3	Reperfusion Injury 01/2016 - 08/2003
2	Thrombocytopenia (Thrombopenia) 01/2022 - 10/2014
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 06/2021 - 04/2003
2	Acute Coronary Syndrome 06/2021 - 12/2006
2	Neoplasms (Cancer) 02/2021 - 10/2007
2	COVID-19 01/2021 - 01/2021
2	Chronic Obstructive Pulmonary Disease (COPD) 12/2020 - 07/2019
2	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 01/2017 - 07/2005
2	Inflammation (Inflammations) 02/2012 - 08/2003
2	Diabetic Nephropathies (Diabetic Nephropathy) 06/2009 - 04/2003
2	Proteinuria 06/2009 - 07/2005
2	Type 2 Diabetes Mellitus (MODY) 06/2009 - 04/2003
1	Thrombosis (Thrombus) 03/2022
1	Liver Cirrhosis (Hepatic Cirrhosis) 02/2021
1	Hypoxia (Hypoxemia) 02/2021
1	Liver Neoplasms (Liver Cancer) 02/2021
1	Hepatocellular Carcinoma (Hepatoma) 02/2021
1	Fibrosis (Cirrhosis) 02/2021
1	Dementia (Dementias) 01/2021
1	Heart Failure 01/2020
1	Respiratory Insufficiency (Respiratory Failure) 07/2019
1	Respiratory Acidosis 07/2019
1	Hyperthermia 01/2018
1	Leukocytosis (Pleocytosis) 01/2018
1	Abdominal Pain (Pain, Abdominal) 01/2017
1	Membranous Glomerulonephritis (Membranous Nephropathy) 01/2017
1	Cardiotoxicity 01/2016
1	Edema (Dropsy) 01/2016
1	Ischemia 01/2016
1	Myocardial Ischemia (Ischemic Heart Diseases) 01/2016
1	Endotoxemia 01/2016
1	Primary Graft Dysfunction 01/2016
1	Dyspnea (Shortness of Breath) 07/2015
1	Disease Progression 11/2014
1	Hemorrhage 10/2014
1	Bacterial Infections (Bacterial Infection) 10/2014
1	Hypovolemia 10/2014
1	Communicable Diseases (Infectious Diseases) 06/2013

Drug/Important Bio-Agent (IBA)

12	Biomarkers (Surrogate Marker)IBA 02/2022 - 06/2013
8	Thrombopoietin (c-mpl Ligand)IBA 06/2021 - 12/2006
5	Proteins (Proteins, Gene)FDA Link 02/2021 - 07/2005
5	fibrin fragment D (D-dimer)IBA 01/2021 - 07/2014
5	ProcalcitoninIBA 01/2018 - 06/2013
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2021 - 10/2014
3	nephrinIBA 02/2007 - 04/2003
2	LipidsIBA 03/2022 - 09/2003
2	AnticoagulantsIBA 01/2022 - 02/2012
2	Matrix Metalloproteinases (MMPs)IBA 01/2022 - 02/2012
2	4,5,6,7- tetrahydroisoxazolo(4,5- c)pyridin- 3- ol (THPO)IBA 06/2021 - 02/2021
2	Small Interfering RNA (siRNA)IBA 02/2021 - 01/2016
2	Messenger RNA (mRNA)IBA 02/2021 - 01/2016
2	CytokinesIBA 01/2021 - 01/2016
2	C-Reactive ProteinIBA 01/2018 - 10/2014
2	Group II Phospholipases A2IBA 01/2018 - 06/2013
2	SteroidsIBA 01/2017 - 07/2005
2	Natriuretic PeptidesIBA 07/2015 - 06/2013
2	Phosphatidylinositols (Phosphatidylinositol)IBA 11/2014 - 12/2004
2	AlbuminsIBA 06/2009 - 04/2003
2	matrigelIBA 10/2007 - 09/2003
2	Platelet Activating FactorIBA 10/2007 - 08/2003
1	NADPH Oxidases (NAD(P)H oxidase)IBA 03/2022
1	NADP (NADPH)IBA 03/2022
1	Proprotein Convertase 9IBA 03/2022
1	Hemoglobins (Hemoglobin)IBA 02/2022
1	proadrenomedullinIBA 02/2022
1	LigandsIBA 01/2022
1	growth arrest-specific protein 6IBA 01/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	brassIBA 01/2021
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2021
1	AntigensIBA 01/2021
1	Carbon DioxideIBA 07/2019
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 02/2016
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2016
1	Protein Isoforms (Isoforms)IBA 11/2014
1	Lipopolysaccharide ReceptorsIBA 10/2014
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 10/2014
1	Lipocalin-2IBA 06/2013
1	AdrenomedullinIBA 06/2013
1	Phospholipases A2 (Phospholipase A2)IBA 06/2013
1	Matrix Metalloproteinase 8 (Neutrophil Collagenase)IBA 02/2013
1	Pentosan Sulfuric Polyester (Pentosan Polysulfate)FDA Link 02/2012

Therapy/Procedure

3	Therapeutics 12/2020 - 01/2018
2	Noninvasive Ventilation 12/2020 - 07/2019
1	Plasma Exchange 01/2017
1	Aftercare (After-Treatment) 01/2016
1	Ligation 01/2016
1	Punctures 01/2016
1	Lung Transplantation 01/2016
1	Endoscopic Hemostasis 10/2014